Related references
Note: Only part of the references are listed.The Durable Clearance of the T315I BCR-ABL Mutated Clone in Chronic Phase Chronic Myelogenous Leukemia Patients on Omacetaxine Allows Tyrosine Kinase Inhibitor Rechallenge
Franck E. Nicolini et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2010)
BCR-ABLT315I transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine:: a new therapeutic challenge?
L. Legros et al.
LEUKEMIA (2007)
Interferon-α or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation
Hugues de Lavallade et al.
BLOOD (2007)
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib
D Marin et al.
CANCER (2005)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Share Paper
